KIT and cancer: In our sequencing studies, solely 17.2% of GISTs harbored non-synonymous missense HSD11B1 mutations, and this low prevalence indicated their role as secondary aberrations in the cancer hallmark of metabolic deregulation among the GISTs that mostly manifested mutated-KIT or -PDGFRA.